Springer G F, Fry W A, Desai P R, Semerdjian R A, Tegtmeyer H, Neybert C G, Scanlon E F
Cancer Detect Prev. 1985;8(1-2):95-100.
We measured the cellular and humoral autoimmune response to carcinoma (CA)-associated T antigen in patients with the earliest clinical stages of lung (T1N0M0) and breast (Tis) CA. We used desialylated MN glycoprotein from healthy human erythrocytes in a single measurement of 1) delayed-type skin hypersensitivity response (DTHR-T) and 2) humoral anti-T response with a solid-phase immunoassay (SPIA-T). DTHR-T detected 19/20 lung CA and 10/12 ductal and 7/10 lobular breast CA patients. Sixteen of 18 stage T1N0M0 lung CA patients had a positive SPIA-T as did 7/8 patients with Tis breast CA. Two of 35 patients with benign lung and 11/144 with benign breast disease had a positive DTHR-T. None of 160 persons with either other non-CA diseases or healthy had a positive DTHR-T. Three of 68 such control subjects had a positive SPIA-T. The difference between CA patients and control populations is statistically highly significant.
我们检测了处于肺癌（T1N0M0）和乳腺癌（Tis）最早临床阶段的患者对癌（CA）相关T抗原的细胞和体液自身免疫反应。我们使用来自健康人红细胞的去唾液酸MN糖蛋白进行了两项检测：1）迟发型皮肤超敏反应（DTHR-T）；2）采用固相免疫测定法（SPIA-T）检测体液抗T反应。DTHR-T检测出19/20例肺癌患者、10/12例导管性乳腺癌患者和7/10例小叶性乳腺癌患者呈阳性。18例T1N0M0期肺癌患者中有16例SPIA-T呈阳性，Tis期乳腺癌患者中有7/8例呈阳性。35例良性肺病患者中有2例DTHR-T呈阳性，144例良性乳腺病患者中有11例呈阳性。160例患有其他非CA疾病的患者或健康人DTHR-T均为阴性。68例此类对照受试者中有3例SPIA-T呈阳性。CA患者与对照人群之间的差异具有高度统计学意义。
